Welcome to the UPF Digital Repository

The IMBG test for evaluating the pharmacodynamic response to immunosuppressive therapy in kidney transplant patients: current evidence and future applications

Show simple item record

dc.contributor.author Pascual, Julio (Pascual Santos)
dc.contributor.author Crespo Barrio, Marta
dc.contributor.author Portolés, José
dc.contributor.author Jimenez, Carlos
dc.contributor.author Ortega-Carrión, Álvaro
dc.contributor.author Diez, Teresa
dc.contributor.author Portero, Isabel
dc.date.accessioned 2024-04-24T06:42:20Z
dc.date.available 2024-04-24T06:42:20Z
dc.date.issued 2023
dc.identifier.citation Pascual J, Crespo M, Portoles J, Jimenez C, Ortega-Carrion A, Diez T, et al. The IMBG test for evaluating the pharmacodynamic response to immunosuppressive therapy in kidney transplant patients: current evidence and future applications. Int J Mol Sci. 2023 Mar 8;24(6):5201. DOI: 10.3390/ijms24065201
dc.identifier.issn 1422-0067
dc.identifier.uri http://hdl.handle.net/10230/59875
dc.description.abstract Immunosuppressive drugs are widely used to prevent rejection after kidney transplantation. However, the pharmacological response to a given immunosuppressant can vary markedly between individuals, with some showing poor treatment responses and/or experiencing serious side effects. There is an unmet need for diagnostic tools that allow clinicians to individually tailor immunosuppressive therapy to a patient’s immunological profile. The Immunobiogram (IMBG) is a novel blood-based in vitro diagnostic test that provides a pharmacodynamic readout of the immune response of individual patients to a range of immunosuppressants commonly used in kidney transplant recipients. Here, we discuss the current approaches used to measure the pharmacodynamic responses of individual patients to specific immunosuppressive drugs in vitro, which can then be correlated with patient’s clinical outcomes. We also describe the procedure of the IMBG assay, and summarize the results obtained using the IMBG in different kidney transplant populations. Finally, we outline future directions and other novel applications of the IMBG, both in kidney transplant patients and other autoimmune diseases.
dc.description.sponsorship The proof-of-concept and TRANSBIO (BHP-IBG-2017-01) IMBG studies were funded by a competitive grant from the European Commission (SME Instrument–Phase II). Project: TRANSBIO (Id 733248) “Cellular BIOtechnology for prognosis and monitoring in renal TRANSplantation”. See https://cordis.europa.eu/project/id/733248. Julio Pascual is supported by grants ISCIII FIS-FEDER 19/0037 and Redinren RD16/0009/0013. Marta Crespo is supported by grants ISCIII FIS-FEDER 20/0090 and Redinren RD16/0009/0013.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher MDPI
dc.relation.ispartof Int J Mol Sci. 2023 Mar 8;24(6):5201
dc.rights © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title The IMBG test for evaluating the pharmacodynamic response to immunosuppressive therapy in kidney transplant patients: current evidence and future applications
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/DOI: 10.3390/ijms24065201
dc.subject.keyword Transplant rejection
dc.subject.keyword Immunosuppressive therapy
dc.subject.keyword Infection
dc.subject.keyword Cellular pharmacodynamics
dc.subject.keyword Immune cell assay
dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/733248
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking